Dose-dependent effects of atorvastatin on myocardial infarction

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Dyslipidemia is a significant risk factor for myocardial infarction (MI) and its complications, contributing to endothelial dysfunction, inflammation, and insulin resistance.
• Statin therapy, including atorvastatin, is a cornerstone in preventing atherosclerosis-related complications.

Purpose of the Study:

• To evaluate the effects of different atorvastatin doses (20 mg/day vs. 40 mg/day) on insulin resistance and metabolic markers in ST-elevation MI patients.
• To assess the impact of early atorvastatin treatment on serum glucose, insulin, adipokine, and ghrelin levels post-MI.

Main Methods:

• A study involving 210 ST-elevation MI patients treated with atorvastatin within 24 hours of MI onset.
• Patients were randomized into two groups: 20 mg/day (n=110) or 40 mg/day (n=100) of atorvastatin.
• Measurements included insulin resistance index, lipid profiles, glucose, insulin, adipokine, and ghrelin levels at days 1 and 12 post-MI.

Main Results:

• Atorvastatin treatment, especially at 40 mg/day, reduced elevated free fatty acid levels during the acute MI phase.
• Low-dose atorvastatin (20 mg/day) normalized adipokine status and significantly reduced glucose (14%) and C-peptide (38%) levels by day 12.
• A decrease in the homeostasis model assessment of insulin resistance index was observed with 20 mg/day atorvastatin on day 12.

Conclusions:

• Atorvastatin therapy influences key biochemical markers of insulin resistance and adipokine status in MI patients.
• Dosing of atorvastatin during and after hospitalization should consider individual patient's metabolic changes.
• Early intervention with atorvastatin may mitigate metabolic derangements associated with MI.